Skip to main content

Southeast BIO (SEBIO) held its Annual Investor & Partnering Forum early this month. In its 15th year, SEBIO’s forum has come to be known as the Southeast’s premier life sciences and medical technology conference. The conference invites emerging companies, industry professionals, entrepreneurs, venture capitalists, investments bankers, corporate executives, and university representatives to facilitate networking and to discuss challenges and opportunities in both the medical technology and biotechnology industry sectors. The conference had nearly 300 attendees this year alone. Twenty-two emerging and promising companies presented funding pitches to investors at the conference, and out of four finalists to present in the EARLY/Stage program, Novocor was selected, by a panel of judges representing four venture funds, as the EARLY/Stage program’s winner.

Novocor’s first product, HypoCore, focuses on putting therapeutic hypothermia as a practical treatment option into the hands of EMS professionals. Therapeutic hypothermia can benefit victims of many different kinds of trauma—stroke, cardiac arrest, heat stroke, traumatic brain injury, and spinal cord injury. Novocor is no stranger to success. In August they raised over $1M in funding, and they have already secured both an NC IDEA grant as well a NC Biotechnology Center loan. In addition, their recent win at SEBIO was featured on WRAL’s TechWire! Congratulations to both Dr. DiMeo and Novocor alike on the fledgling company’s continued success.

To read the full press-release, please see the following link:

Comments are closed.